ABI-110 Low Dose

Small molecule

ABI-110 Low Dose is one of 18 small molecule programs targeting Polypoidal choroidal vasculopathy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polypoidal Choroidal VasculopathyActive, not recruiting

Polypoidal Choroidal VasculopathyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Polypoidal Choroidal Vasculopathy

#DrugCompanyPhaseTrials

Kenalog

BBausch Health Americas, Inc.

Approved

1 2

Intravitreal Aflibercept

Regeneron

Approved

3 3

Eylea

Regeneron

Phase 3

6 4

Vabysmo

Roche

Phase 3

2 5

Beovu

Novartis

Phase 3

1 6

Verteporfin PDT

Novartis

Approved

2 7

Avastin

BBio-Thera Solutions

Phase 3

—8

Anti-VEGF Drug

FFirst Affiliated Hospital of Chongqing Medical University

Approved

1 9

Izervay

Astellas

Phase 2

1 10

Lucentis

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1/2Active, not recruiting

Polypoidal Choroidal Vasculopathy

NCT06550011

Clinical

Trials by Indication[1]

Polypoidal choroidal vasculopathy1 trial

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Active, not recruiting·AAvirmax Biopharma Inc·Phase 1/2·NCT06550011·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABI-110 Low Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABI-110 Low Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABI-110 Low Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avirmax Biopharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAvirmax Biopharma Inc

ABI-110 Low Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Polypoidal choroidal vasculopathy1 trial

References

Drug Info

Quick Facts

Related News